Published in Cancer Weekly, August 7th, 2007
The paper is the result of pre-clinical research conducted by Alfacell and collaborators at Martin-Luther University in Halle-Wittenberg, Germany that investigated the relationship between the stability and ribonucleolytic activity of ONCONASE and several genetically engineered variants of ONCONASE, and their cytostatic and cytotoxic properties in several tumor cell lines. Human tumor cell lines used in the study included NCI-H2452...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.